NASDAQ:ALVR

AlloVir Competitors

$22.76
-0.45 (-1.94 %)
(As of 04/12/2021 05:20 PM ET)
Add
Compare
Today's Range
$21.70
Now: $22.76
$23.49
50-Day Range
$20.81
MA: $29.84
$41.61
52-Week Range
$18.15
Now: $22.76
$48.96
Volume347,804 shs
Average Volume369,727 shs
Market Capitalization$1.48 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

AlloVir (NASDAQ:ALVR) Vs. ADPT, KOD, VIR, CBPO, ALLO, and IOVA

Should you be buying ALVR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to AlloVir, including Adaptive Biotechnologies (ADPT), Kodiak Sciences (KOD), Vir Biotechnology (VIR), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), and Iovance Biotherapeutics (IOVA).

Adaptive Biotechnologies (NASDAQ:ADPT) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Adaptive Biotechnologies and AlloVir, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adaptive Biotechnologies02402.67
AlloVir00403.00

Adaptive Biotechnologies currently has a consensus price target of $61.40, indicating a potential upside of 52.85%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Adaptive Biotechnologies.

Institutional and Insider Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Adaptive Biotechnologies and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adaptive Biotechnologies-132.32%-20.15%-13.09%
AlloVirN/AN/AN/A

Earnings & Valuation

This table compares Adaptive Biotechnologies and AlloVir's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$85.07 million65.74$-68,610,000.00($1.01)-39.77
AlloVirN/AN/AN/AN/AN/A

AlloVir has lower revenue, but higher earnings than Adaptive Biotechnologies.

Summary

AlloVir beats Adaptive Biotechnologies on 5 of the 8 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Kodiak Sciences and AlloVir, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kodiak Sciences17402.25
AlloVir00403.00

Kodiak Sciences currently has a consensus price target of $129.9091, indicating a potential upside of 22.32%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Kodiak Sciences.

Institutional and Insider Ownership

82.3% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 39.3% of Kodiak Sciences shares are owned by insiders. Comparatively, 1.0% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Kodiak Sciences and AlloVir's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A$-47,370,000.00($1.25)-84.96
AlloVirN/AN/AN/AN/AN/A

Profitability

This table compares Kodiak Sciences and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kodiak SciencesN/A-32.32%-23.86%
AlloVirN/AN/AN/A

Summary

AlloVir beats Kodiak Sciences on 4 of the 6 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and price targets for Vir Biotechnology and AlloVir, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vir Biotechnology20502.43
AlloVir00403.00

Vir Biotechnology presently has a consensus price target of $66.00, indicating a potential upside of 53.06%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Vir Biotechnology.

Institutional & Insider Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by company insiders. Comparatively, 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Vir Biotechnology and AlloVir's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$8.09 million682.16$-174,680,000.00($5.76)-7.49
AlloVirN/AN/AN/AN/AN/A

AlloVir has lower revenue, but higher earnings than Vir Biotechnology.

Profitability

This table compares Vir Biotechnology and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vir Biotechnology-339.61%-47.11%-39.44%
AlloVirN/AN/AN/A

Summary

AlloVir beats Vir Biotechnology on 5 of the 9 factors compared between the two stocks.

China Biologic Products (NASDAQ:CBPO) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and price targets for China Biologic Products and AlloVir, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Biologic Products0000N/A
AlloVir00403.00

AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's higher probable upside, analysts clearly believe AlloVir is more favorable than China Biologic Products.

Institutional & Insider Ownership

34.8% of China Biologic Products shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Comparatively, 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares China Biologic Products and AlloVir's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Biologic Products$503.70 million9.26$138.81 million$4.2827.69
AlloVirN/AN/AN/AN/AN/A

China Biologic Products has higher revenue and earnings than AlloVir.

Profitability

This table compares China Biologic Products and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Biologic Products27.43%8.32%7.64%
AlloVirN/AN/AN/A

Summary

China Biologic Products beats AlloVir on 6 of the 8 factors compared between the two stocks.

Allogene Therapeutics (NASDAQ:ALLO) and AlloVir (NASDAQ:ALVR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Earnings and Valuation

This table compares Allogene Therapeutics and AlloVir's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-16.16
AlloVirN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for Allogene Therapeutics and AlloVir, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allogene Therapeutics031302.81
AlloVir00403.00

Allogene Therapeutics presently has a consensus price target of $52.0833, indicating a potential upside of 76.08%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 114.19%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Allogene Therapeutics.

Profitability

This table compares Allogene Therapeutics and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allogene TherapeuticsN/A-27.59%-24.97%
AlloVirN/AN/AN/A

Institutional & Insider Ownership

59.9% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 31.3% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

AlloVir beats Allogene Therapeutics on 4 of the 7 factors compared between the two stocks.

AlloVir (NASDAQ:ALVR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Earnings & Valuation

This table compares AlloVir and Iovance Biotherapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/AN/AN/AN/A
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-18.50

Analyst Ratings

This is a breakdown of current recommendations for AlloVir and Iovance Biotherapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AlloVir00403.00
Iovance Biotherapeutics01902.90

AlloVir presently has a consensus target price of $48.75, indicating a potential upside of 114.19%. Iovance Biotherapeutics has a consensus target price of $50.50, indicating a potential upside of 71.71%. Given AlloVir's stronger consensus rating and higher probable upside, analysts plainly believe AlloVir is more favorable than Iovance Biotherapeutics.

Profitability

This table compares AlloVir and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AlloVirN/AN/AN/A
Iovance BiotherapeuticsN/A-50.64%-45.64%

Institutional & Insider Ownership

32.1% of AlloVir shares are held by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are held by institutional investors. 1.0% of AlloVir shares are held by insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

AlloVir beats Iovance Biotherapeutics on 4 of the 7 factors compared between the two stocks.


AlloVir Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$40.17-0.6%$5.59 billion$85.07 million-42.28Insider Selling
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$106.20-2.7%$5.58 billionN/A-45.78
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$43.12-0.0%$5.52 billion$8.09 million-18.27Gap Down
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.52-0.4%$4.64 billion$503.70 million33.11
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$29.58-11.0%$4.62 billionN/A-13.89Analyst Report
News Coverage
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$29.41-2.7%$4.32 billionN/A-15.32News Coverage
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$68.82-2.0%$4.30 billion$20,000.00-4.90
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$67.45-2.2%$3.30 billionN/A-38.76
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$69.04-1.9%$3.14 billion$125.57 million-40.37
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$39.25-8.7%$3.13 billion$50.04 million0.00News Coverage
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.77-2.6%$3.04 billionN/A0.00
Vericel logo
VCEL
Vericel
1.1$58.18-0.7%$2.68 billion$117.85 million-5,818,000.00
Editas Medicine logo
EDIT
Editas Medicine
1.6$39.51-0.1%$2.66 billion$20.53 million-22.71Gap Down
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.94-8.2%$1.95 billion$31.43 million-4.75
bluebird bio logo
BLUE
bluebird bio
1.8$27.98-0.6%$1.89 billion$44.67 million-2.55
NantKwest logo
NK
NantKwest
1.1$16.87-10.8%$1.84 billion$40,000.00-23.76
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$9.50-7.5%$1.81 billion$48.83 million-12.50
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$22.26-7.3%$1.81 billionN/A-10.40
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.06-0.4%$1.58 billion$102.43 million-18.43Analyst Upgrade
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.03-2.4%$1.58 billionN/A-47.99News Coverage
Immunovant logo
IMVT
Immunovant
1.8$15.27-2.7%$1.54 billionN/A-11.84
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$31.43-6.4%$1.50 billionN/A0.00
REGENXBIO logo
RGNX
REGENXBIO
1.6$33.75-4.2%$1.49 billion$35.23 million-13.61
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$30.71-6.3%$1.41 billionN/A0.00News Coverage
Alector logo
ALEC
Alector
1.3$16.80-3.4%$1.38 billion$21.22 million-7.53
Replimune Group logo
REPL
Replimune Group
1.5$29.35-2.5%$1.36 billionN/A-16.58
Translate Bio logo
TBIO
Translate Bio
1.6$17.12-0.8%$1.30 billion$7.80 million-16.00
Ocugen logo
OCGN
Ocugen
1.1$6.68-4.2%$1.26 billionN/A-4.51
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.70-0.5%$1.15 billionN/A-2.97
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.29-2.2%$1.15 billion$100.56 million0.00
Mesoblast logo
MESO
Mesoblast
1.4$8.45-0.7%$1.10 billion$32.16 million-9.60
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.16-0.3%$1.04 billionN/A0.00
Scholar Rock logo
SRRK
Scholar Rock
1.5$27.84-7.5%$1.03 billion$20.49 million-11.55
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.70-1.8%$997.28 million$356.07 million6.72
Curis logo
CRIS
Curis
1.3$10.82-6.3%$990.24 million$10 million-13.20
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$25.00-15.2%$944.03 millionN/A0.00Analyst Report
High Trading Volume
News Coverage
Gap Down
Cortexyme logo
CRTX
Cortexyme
1.3$31.88-5.4%$942.12 millionN/A-13.28
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$19.30-4.1%$922.43 million$42.74 million-214.44News Coverage
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.75-0.5%$894.42 millionN/A-4.09High Trading Volume
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.07-0.1%$887.01 million$250,000.00-7.14News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.41-2.3%$883.45 million$69.89 million-4.39
Passage Bio logo
PASG
Passage Bio
1.8$15.99-2.2%$879.60 millionN/A0.00
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.03-0.0%$839.78 millionN/A-9.10Analyst Report
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.56-2.6%$832.47 million$2.51 million-3.98
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.34-0.6%$813.97 millionN/A0.00Lockup Expiration
Cellectis logo
CLLS
Cellectis
1.3$18.66-6.8%$798.28 million$22.99 million-9.93Gap Up
Inhibrx logo
INBX
Inhibrx
1.6$19.85-3.3%$773.83 millionN/A0.00
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.97-1.6%$772.67 million$1.12 million-5.02
Athira Pharma logo
ATHA
Athira Pharma
2.2$16.80-13.6%$708.25 millionN/A0.00Analyst Upgrade
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.24-12.0%$656.00 million$5.78 million-9.50
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.